Secondary GBM harbors IDH1 and IDH2 mutations, which can convert α-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG) to initiate tumorigenesis (6). Here, IDH1 is linked to glioblastoma.